Cardiac dysfunction leading to heart failure can result from anticancer drug-induced cardiotoxicity. It is the
second cause of morbidity and mortality among cancer survivors, a group that is growing due to improved
cancer treatments. No reliable early markers of drug-induced cardiotoxicity have been identified, and safe,
effective drugs to prevent anticancer drug-induced cardiotoxicity are not available. Taking into account the
extensive economic and social costs of this condition, it is imperative to develop both early
cardiotoxicity markers and efficacious drugs to protect cancer patients against cardiotoxic
anticancer drugs. The Cardio-Oncology consortium brings together cardiologists (D. Cardinale),
cardiobiologists (C. Nebigil), oncologists (M.W. Chan), chemo-bioinformaticians (I. Tetko), stem cell
cardiobiologists (R. Passier) and medicinal chemists (L. Désaubry & Ö. Reis). Together, the consortium aims
to 1) develop cardio-protective therapeutics, including in silico, in vitro and in vivo testing, and
benchmarking in mouse models and human stem cells, 2) validate and analyse predictive biomarkers of
cardiotoxicity in European and Taiwanese cancer patients to detect early cardiac dysfunction and to define
the distinctive etiopathogenetic features of cardiotoxicity. The Cardio-Oncology project will deliver biomarker
candidates and cardio-protective drug candidates that can be further developed by pharmaceutical and
diagnostic companies aiming to improve cancer care.
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
EUROPEAN INSTITUTE OF ONCOLOGY
CND Centre national de la recherche scientifique, CNRS
MIRA INSTITUTE-UNIVERSITY OF TWENTE-THE NETHERLANDS
NATIONAL CHUNG CHENG UNIVERSITY
NOBEL PHARM ULKAR HOLDING A.S.
CNRS-FACULTE DE PHARMACIE DE L'UNIVERSITE DE STRASBOURG
Help of the ANR 119,414 euros
Beginning and duration of the scientific project: April 2017 - 36 Months